Provided by Tiger Trade Technology Pte. Ltd.

Arlington Asset Investment Corp

4.84
0.0000
Volume:- -
Turnover:- -
Market Cap:137.08M
PE:-61.27
High:4.84
Open:4.84
Low:4.84
Close:4.84
52wk High:4.84
52wk Low:2.53
Shares:28.32M
Float Shares:27.03M
Volume Ratio:- -
T/O Rate:- -
Dividend:0.23
Dividend Rate:4.65%
EPS(TTM):-0.0790
EPS(LYR):0.0920
ROE:0.20%
ROA:0.04%
PB:0.76
PE(LYR):52.61

Loading ...

“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom

GlobeNewswire
·
Nov 14, 2025

Longeveron® to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

GlobeNewswire
·
Sep 22, 2025

FDA Approves LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease

GlobeNewswire
·
Aug 30, 2025

Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update

GlobeNewswire
·
Aug 12, 2025

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

GlobeNewswire
·
Aug 08, 2025

Annovis Completes Full Patent Transfer to Crystal Buntanetap

GlobeNewswire
·
Aug 07, 2025

Two-Year Real-World Study of LEQEMBI® in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

GlobeNewswire
·
Jul 30, 2025

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

GlobeNewswire
·
Jul 30, 2025

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

GlobeNewswire
·
Jul 29, 2025

Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease

GlobeNewswire
·
Jul 29, 2025

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod’s Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

GlobeNewswire
·
Jul 28, 2025

CervoMed to Present New Data from Phase 2b RewinD-LB Study at AAIC 2025 and Host Conference Call on July 28, 2025

GlobeNewswire
·
Jul 25, 2025

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

GlobeNewswire
·
Jul 24, 2025

NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025

GlobeNewswire
·
Jul 22, 2025

Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC

GlobeNewswire
·
Jul 16, 2025

Cerevance Announces Presentations at the Alzheimer's Association International Conference 2025

GlobeNewswire
·
Jul 11, 2025

CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025

GlobeNewswire
·
Jul 08, 2025